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osteogenesis
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Abstract
Background: Skeletal muscle fibrosis caused by an increase in collagen deposition often occurs after distraction
osteogenesis. Although studies are available reporting the effects of platelet-rich plasma (PRP) on tissue healing
following injury, current findings remain controversial. This study focused on determining whether PRP reduces
skeletal muscle fibrosis caused by distraction osteogenesis.
Methods: Tibial osteotomies were performed on 8-week-old wild type mice, and tibiae were distracted at a rate of
0.42 mm/day for 2 weeks, starting 1 week after osteotomy. Immediately after distraction was completed (3 weeks
after osteotomy), PRP or phosphate buffered saline (as a sham) was injected into the gastrocnemius (GC) muscle.
The GC muscles were harvested and analyzed.
Results: The amount and area of collagenous tissue increased in both the PRP and control groups following distraction
osteogenesis, but the changes were not significantly different between both groups at all time points (p = 0.89, 0.45, 0.33
and 0.52 at 4, 6, 8 and 10 weeks).
Conclusion: From this study, our results suggest that PRP did not significantly reduce skeletal muscle fibrosis due to
distraction osteogenesis.
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Background
Distraction osteogenesis is a useful treatment for trauma
and musculoskeletal disorders that result in limb length
discrepancy and short stature (Ilizarov 1990). However,
distraction osteogenesis causes a specific kind of skeletal
muscle damage (Williams et al. 1999; Williams et al.
1998; Williams et al. 2001; De Deyne et al. 2000; Antoci
et al. 2006; Tonogai et al. 2015). This extremely severe
skeletal muscle damage is characterized by repeated
regular and gradual distraction of the muscle during dis-
traction phase (Tonogai et al. 2015). Fibroblasts migrate
to the damaged site and proliferate, and fibrous tissue is
formed by increased production of collagen (Tonogai et
al. 2015). Therefore, fibrosis often results in common
clinical complications such as skeletal muscle contrac-
ture (Antoci et al. 2006; Paley 1999).
Platelet-rich plasma (PRP), an easily obtainable product,
is the plasma fraction derived from a person’s own blood,
and it contains high concentrations of platelets including
growth factors (GFs), which are known to play a critical
role in tissue healing (Molloy et al. 2003; Anitua et al.
2006; Wang et al. 2006; DeLong et al. 2012). However, not
all studies have found positive outcomes of PRP (Nin et al.
2009; de Vos et al. 2010; de Jonge et al. 2011; Schepull et
al. 2011). In terms of skeletal muscle, some authors report
that PRP enhances the skeletal muscle healing process
(Menetrey et al. 2000; Huard et al. 2002; Wright-
Carpenter et al. 2004; Järvinen et al. 2007; Sanchez et al.
2007; Cunha et al. 2014; Contreras-Muñoz et al. 2017),
while Harris et al. report the development of thrombosis,
necrosis, and calcium deposition histologically at intra-
muscular PRP injection sites and thus the potential for
negative effects of PRP injections (Harris et al. 2012), and
Kelc et al. report concerns that PRP injection may lead to
fibrosis (Kelc et al. 2015).
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Some articles describe the osteogenic effect of PRP in-
jection during osteogenesis (Kitoh et al. 2004; Ali et al.
2015). However, no studies have investigated the effect
of PRP on skeletal muscle fibrosis caused by distraction
osteogenesis, although we reported the evaluation of the
skeletal muscle after distraction osteogenesis in mice
without any additional intervention such as PRP admin-
istration (Tonogai et al. 2015). We hypothesized that
PRP has favorable effects on skeletal muscle fibrosis
following distraction osteogenesis, and in this study we
investigated specifically whether PRP reduces skeletal
muscle fibrosis and what ratio PRP influences on skeletal
muscle fibrosis following distraction osteogenesis in mice.
Methods
Experimental animals
Eight-week-old wild-type (WT) male (C57BL/6xDBA/2)
F1 (BDF1) mice (weight 23–27 g) purchased from Japan
SLC Inc. (Shizuoka, Japan), were used in this study. All
animal experiments were approved by the Animal Care
and Use Committee of Tokushima University Graduate
School and were performed according to the Guidelines
for the Care and Use of Laboratory Animals at Tokush-
ima University Graduate School.
Distraction osteogenesis
The operative procedure was performed with an external
fixator for limb lengthening as described previously
(Tonogai et al. 2015). The external fixator consisted of 2
open aluminum rings, 2 stainless steel screws, and 6 nuts.
Mice were anesthetized with an intraperitoneal injection
of 2.5% tribromoethanol. The external fixator was applied
with super glue to the right tibia, using two 27 G needles
for each proximal and distal ring. A transverse osteotomy
was performed with a No. 11 scalpel blade at the
mid-shaft of the tibia between the 2 rings without any
additional soft tissue damage. The wound was closed with
5–0 nylon suture after completion of the osteotomy. The
mice were allowed free unrestricted weightbearing.
The protocol of the distraction osteogenesis is shown in
Fig. 1. We performed distraction osteogenesis of the right
hind limbs for total 80 mice, and assigned 40 mice into
non-PRP group and the remaining 40 mice into PRP
group, and 10 mice in each group were sacrificed at 4, 6,
8, and 10 weeks after osteotomy (n = 10/group/week).
Briefly, after a lag phase of 1 week, distraction was carried
out at a rate of 0.21 mm every 12 h for 2 weeks, because a
faster rate might cause peroneal nerve palsy resulting in
denervation change of the muscle and a slower rate might
lead to less muscle fibrosis. The length of the distraction
gap seen on X-ray was approximately 6 mm at the end of
the distraction phase. PRP 40 μl was injected directly into
each distracted right gastrocnemius (GC) muscle in a total
of 40 mice (PRP group) immediately after completing dis-
traction osteogenesis (3 weeks after osteotomy), because
muscle fibrosis was very severe at that time point as we
reported previously (Tonogai et al. 2015). The injection
site was prepped in a typical sterile fashion, and the needle
was exactly inserted through the skin into the belly of the
right GC muscle under ultrasound. Half of the volume,
20 μl, was injected into the medial right GC, and the
remaining half was injected into the lateral right GC. For
the sham group, 40 μl phosphate buffered saline (PBS)
was injected into each right distracted GC muscle in a
total of 40 mice in the same manner (non-PRP group).
PRP preparation
We prepared allogenic PRP-containing leukocytes (L-PRP)
using the BS Medical Platelet Concentration System (BS
Medical, Tokyo, Japan), which was specialized for small ani-
mals like mouse, following the manufacturer’s instructions.
L-PRP were prepared in a two-step centrifugation process.
Fig. 1 Experimental protocol and representative radiographs of distraction osteogenesis from 0 to 10 weeks after osteotomy
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Briefly, 500 μl was withdrawn via intra-cardiac puncture
from 1 adult male mouse (11 weeks old). Then, 5 ml whole
blood from 10 mice was pooled and collected in a blood
tube including 0.5 ml acid citrate dextrose (ACD) solution
which was anticoagulant. The whole blood was centrifuged
at 550 G (1800 rpm) for 8 min, resulting in the formation
of 3 layers: plasma, buffy coat including PRP component,
and red blood cell (RBC) layer (Fig. 2). As much as possible,
the top two-thirds of the supernatant was obtained for PRP
preparation and was centrifuged again at 380 G (1500 rpm)
for 6 min, resulting in the formation of 3 layers: plasma,
buffy coat including PRP component, and a small RBC
layer. The buffy coat including 500 μl PRP was carefully
isolated and harvested from the tube. In this study, a total
of 20 ml of whole blood was collected from 40 adult male
11-week-old mice, and a total of 2 ml PRP was obtained.
PRP was used immediately after preparation rather than
storing for later use, to minimize any effects of prolonged
storage or freeze/thaw cycles and in accordance with how it
is typically prepared and applied clinically (Delos et al.
2014). Next, 40 μl of PRP was injected into each GC of the
distracted hind limb (20 μl into the medial GC and 20 μl
into the lateral GC) in a total of 40 mice (PRP group) just
after distraction osteogenesis finished. The volume of injec-
tion was consistent with another study using a mouse
muscle injury model (Qu and Huard 2000; Ota et al. 2011;
Terada et al. 2013). The remaining 400 μl PRP was
subjected to measurement, consisting of white blood cell
(WBC), RBC, and platelet counts, and assessment of the
GFs vascular endothelial growth factor (VEGF), platelet-
derived growth factor-AB (PDGF-AB), and transforming
growth factor–β1 (TGF-β1).
Assessment of WBC, RBC, platelets, and GFs
WBC, RBC, and platelet counts in whole blood and PRP
were determined using an automated cell counter to de-
termine whether platelets were enriched in PRP. Concen-
trations of VEGF (R&D Systems, Minneapolis, MN, US),
PDGF-AB (R&D Systems, Minneapolis, MN, US), and
TGF-β1 (R&D Systems, Minneapolis, MN, US) were de-
termined by enzyme-linked immunosorbent assay (ELISA)
to detect and quantify the presence of GFs. Analyses were
then performed according to the manufacturer’s instruc-
tions. Briefly, samples and standards were added to 96 GF
antibody-coated well plates. After incubation and removal
of unbound substances, a secondary antibody was added.
This was followed by further washing and incubation with
a substrate. The color reaction was stopped, and optical
density was measured at a wavelength of 495 nm.
Tissue preparation
We chose GC muscle because we could obtain enough
muscle volume to evaluate in histological analysis and
hydroxyproline assessment, although tibialis antetior (TA)
muscle also underwent fibrosis. Right GC muscles in each
group were harvested, weighed, and flash frozen in liquid
nitrogen-precooled isopentane at 4, 6, 8, and 10 weeks
after osteotomy (n = 10/group/week). Then, all samples
were cut longitudinally in the middle of the right GC
muscle and divided into medial and lateral parts. The
medial GC muscles from each group per week were used
for histological analysis (n = 10/group/week). The lateral
GC muscles from each group per week were used for
hydroxyproline assay to assess collagen content (n = 10/
group/week).
Histological analysis
A cryostat was used to make 10-μm thick transverse
sections of the central part of the belly of the GC muscle.
Sections were mounted on MAS-coated slides (Matsunami
Glass Industries, Osaka, Japan) and fixed in ice-cold
acetone for 10 min. Sections were stained with Masson’s
trichrome for histological examination of skeletal muscle
fibrosis. The degree of fibrosis was evaluated in Mason’s
trichrome staining images. Fibrotic blue area was measured
in all fields using the image analysis software WinROOF
(Mitani Corporation, Fukui, Japan), and was calculated to
estimate the percentage of fibrosis development.
Fig. 2 Whole blood in a tube containing ACD, which was anticoagulant,
after centrifuging shows 3 layers comprising clear plasma, buffy coat
including PRP component, and RBC layer
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Hydroxyproline assay for collagen content
Hydroxyproline is a major constituent of collagen and is
highly expressed in fibrous tissue (Mu et al. 2010). Total
hydroxyproline content was determined in the GC muscle
using a colorimetric assay kit (BioVision, Milpitas, CA) to
evaluate fibrotic changes in the distracted GC muscles, as
described previously (Tonogai et al. 2015). Briefly, GC
muscles were hydrolyzed in 12 N HCl at 120 °C for 3 h.
After hydrolysis, samples were neutralized and treated
with chloramine T solution for 5 min at room temperature
followed by dimethylamine borane solution for 90 min at
60 °C. Absorbance was measured at 560 nm. Hydroxypro-
line concentration was determined by comparison with a
standard curve prepared from pure hydroxyproline of
known concentrations.
Statistical analysis
Data are expressed as mean ± standard error of mean
(SEM). Unpaired Student’s t-test was used to analyze
differences between the PRP and non-PRP groups at 4,
6, 8, and 10 weeks after osteotomy. P < .05 was consid-
ered statistically significant.
Results
Hematological analysis of WBC, RBC, and platelets
The WBC count was approximately 2.5 times higher in
PRP (11,200/μl) than in whole blood (4500/μl), indicating
that the prepared PRP was actually L-PRP (Table 1). The
RBC count was very low in PRP (4 × 104/μl) compared
with whole blood (757 × 104/μl; Table 1). The platelet
count was approximately 7.7 times higher in PRP (162 ×
104/μl) than in whole blood (21 × 104/μl) (Table 1).
Measurement of GFs using ELISAs
The concentration of VEGF, PDGF-AB, and TGF-β1 were
all higher in PRP than in plasma (Table 2). VEGF was
approximately 1.7 times higher at 69.7 pg/ml; PDGF-AB
was approximately 3.4 times higher at 9.8 ng/ml; and
TGF-β1 was approximately 7.4 higher at 700.2 ng/ml.
Muscle wet weight
We evaluated muscle wet weight, because it included
moisture reflecting muscle edema. Wet weight of the
GC muscles in the non-PRP and PRP groups decreased
at 4 weeks after osteotomy (0.114 ± 0.002 g and 0.116 ±
0.004 g, respectively) and then gradually increased from
6 weeks (Fig. 3). Muscle weight improved to 0.160 ±
0.009 g in the non-PRP group and 0.161 ± 0.006 g in
PRP group at 8 weeks, and to 0.155 ± 0.005 g and 0.151
± 0.007 g, respectively, at 10 weeks. Thus, findings at 8
and 10 weeks were almost the same as the 0-week level
in both groups (Fig. 3). Weight in the PRP group did not
differ significantly from that of the non-PRP group at
any time point (p = 0.68, 0.91, 0.89 and 0.46 at 4, 6, 8
and 10 weeks).
Fibrosis
Masson’s trichrome staining of representative images of
non-PRP and groups PRP are shown in Fig. 4a. The
appearance of severely fibrotic areas was similar in both
groups at 4 weeks after osteotomy. The area of collagen
deposition gradually decreased but persisted in both
groups at 6, 8, and 10 weeks, at similar levels in both
groups. The ratio of the fibrotic area to the total
cross-sectional area was of the GC muscles in both groups
remarkably increased at 4 weeks after osteotomy
(non-PRP: 44.6 ± 1.5%; PRP: 43.7 ± 1.5%) and then grad-
ually decreased at 6, 8, and 10 weeks (Fig. 4b). At 6, 8, and
10 weeks, there were no significant differences between
the non-PRP and PRP groups (30.3 ± 0.6% vs 31.1 ± 1.4%,
p = 0.73; 26.6 ± 1.1% vs 24.6 ± 1.2%, p = 0.35; and 22.3 ±
1.0% vs 21.1 ± 0.8%, p = 0.49, respectively; Fig. 4b).
The total hydroxyproline content of the GC muscles in
both groups remarkably increased at 4 weeks after osteot-
omy (non-PRP: 4.39 ± 0.08 μg/mg tissue; PRP: 4.21 ±
0.07 μg/mg tissue) and then gradually decreased at 6, 8,
and 10 weeks (Fig. 4c), consistent with the findings of Mas-
son’s trichrome staining. At 6, 8, and 10 weeks, there were
no significant differences between the non-PRP and PRP
groups (2.80 ± 0.06 μg/mg tissue vs 3.00 ± 0.05 μg/mg tis-
sue, p = 0.45; 2.72 ± 0.17 μg/mg tissue vs 2.57 ± 0.09 μg/mg
tissue, p = 0.33; and 2.47 ± 0.08 μg/mg tissue vs 2.41 ±
0.09 μg/mg tissue, p = 0.52, respectively; Fig. 4c).
Discussion
This study, which was designed to investigate whether
PRP reduced skeletal muscle fibrosis after distraction
osteogenesis, found that distraction osteogenesis caused
fibrous tissue formation in the GC muscles in the
non-PRP and PRP groups. This fibrosis was remarkably
increased at 4 weeks after osteotomy and subsequently de-
creased but persisted in both groups at 6, 8, and 10 weeks.
Table 1 WBC, RBC, and platelet counts in whole blood and PRP
WBC (/μl) RBC (×104/μl) Platelet (×104/μl)
Whole blood 4500 757 21
PRP 11,200 9 162
Normal values: WBC 5000–13,700/μl, RBC 790–1010 × 104/μl,
Platelet 60–120 × 104/μl
WBC white blood cell, RBC red blood cell, PRP platelet-rich plasma
Table 2 Concentration of VEGF, PDGF-AB, and TGF-β1 in
plasma and PRP
VEGF (pg/ml) PDGF-AB (ng/ml) TGF-β1 (ng/ml)
Plasma 41.6 2.9 94.0
PRP 69.7 9.8 700.2
VEGF vascular endothelial growth factor, PDGF-AB platelet-derived growth
factor-AB, TGF-β1 transforming growth factor-β1, PRP platelet-rich plasma
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Although gradual decrease of fibrosis at 6, 8, and 10 weeks
reflected muscle remodeling or healing as we reported
previously (Tonogai et al. 2015), we found no significant
differences in total hydroxyproline content, indicative of
skeletal muscle fibrosis, between the non-PRP and PRP
groups at any time point.
Although distraction osteogenesis does not directly
damage muscle such as attack injury, distraction osteogen-
esis causes severe skeletal muscle damage by pulling
strength (Tonogai et al. 2015). We initially expected that
PRP might significantly reduce skeletal muscle fibrosis
after distraction osteogenesis. However, our study showed
no positive effect on muscle following distraction osteo-
genesis after treatment with PRP, similar to the findings of
(Delos et al. 2014). They reported a high percentage of
fibrous tissue in the PRP group compared with the control
group in a rat GC contusion model. We are unable to
clearly explain this observation, but various factors may be
involved in the process. A possible reason could be that
our distraction osteogenesis model involved more severe
muscle damage than simple muscle injury. Although PRP
might be effective in slight or mild skeletal muscle injury,
our results might suggest that severe skeletal muscle dam-
age during osteogenesis exceeds the tissue healing func-
tion of PRP.
PRP contains various GFs. For examples, PDGF stimu-
lates mitogenesis of mesenchymal cells and chemotaxis
(Hammond et al. 2009). VEGF leads to increased angio-
genesis and decreased fibrosis in injured skeletal muscle
(Deasy et al. 2009; Ranzato et al. 2009). However, besides
the beneficial effects, PRP also contains significantly
higher concentrations of TGF-β1. TGF-β1 is a key factor
in the development of fibrosis (Border and Noble 1994)
because it has the ability to stimulate collagen synthesis
and fibroblast proliferation contributes to increased colla-
gen deposition (Ignotz and Massague 1986). Therefore,
PRP containing TGF-β1 might potentially stimulate
skeletal muscle fibrosis (Massagué et al. 1986; Allen and
Boxhorn 1989; Li and Huard 2002; Borrione et al. 2010;
Visser et al. 2010), although there are reports that
PRP-treated muscles showed reduction of fibrosis
(Gigante et al. 2012; Gigante et al. 2014; Cianforlini et al.
2015). Nevertheless, an increase in fibrosis can accelerate
the fibrotic healing process after tendon and ligament in-
juries (Hildebrand and Frank 1998; Mishra et al. 2009;
Beye et al. 2008; Fallouh et al. 2010; Huang and Whang
2010; Iqbal et al. 2011), with the presence of high concen-
trations of TGF-β1 in PRP potentially promoting fibrosis
in injured skeletal muscle. Conversely, Li et al. reported
that neutralizing TGF-β1 in PRP reduced muscle fibrosis,
and Terada et al. and Huard J et al. also reported that PRP
injection and administration of losartan (an antifibrotic
agent) decreased muscle fibrosis in an animal muscle in-
jury model (Huard et al. 2002; Terada et al. 2013; Li et al.
2016). Blocking of factors that cause fibrosis like TGF-β1
in PRP might be beneficial.
We selected L-PRP because it can be beneficial,
stimulating the immune response against infections
(Cieslik-Bielecka et al. 2007; Moojen et al. 2008); promot-
ing chemotaxis, proliferation, and differentiation of cells;
and inducing angiogenesis (Wrotniak et al. 2007). In con-
trast, Zhou H al. reported that L-PRP may be detrimental
to the healing of injured tissue because it induces catabolic
and inflammatory effects on cells and may prolong the ef-
fects in healing tissue, while pure-PRP (P-PRP) may result
in formation of excessive scar tissue due to the strong
potential of P-PRP to induce inordinate cellular anabolic
effects when used to treat acutely injured tissue (Zhou et
al. 2015). The presence or absence of WBC might also
affect the results because the exact role of leukocytes in
PRP is unclear as yet. Further studies are required to
clarify the ideal PRP formulations including WBC.
Fig. 3 Time course of changes in wet weight of GC muscles of the non-PRP and PRP groups at 4, 6, 8, and 10 weeks after osteotomy. Data
represent mean ± SEM (n = 10/group/week)
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There are limitations in this study. Of course, this result
does not correspond to the clinical scenario in patients,
because there is race discrepancy between human and
mouse and distraction osteogeneis procedure for mouse is
not exactky same as the one for human. First limitation is
that muscle function, like ankle plantarflexion torque, was
not measured (Tonogai et al. 2015). Analysis for TA
muscles might be also necessary. Second, osteotomy site,
distraction speed, period, or length might also affect the
results. Third, PRP-related factors such as variations in
Fig. 4 a Representative cross-sections of GC muscles stained with Masson’s trichrome in the non-PRP and PRP groups at 4, 6, 8, and 10 weeks after
osteotomy (Bar, 100 μm). b The ratio of the fibrotic area to the total muscle cross sectional area in the GC muscles of the two groups. Data represent
mean ± SEM (n= 10/group/week). c Total hydroxyproline content in the GC muscles of the two groups. Data represent mean ± SEM (n= 10/group/week)
Tonogai et al. Journal of Experimental Orthopaedics  (2018) 5:26 Page 6 of 8
preparations and dosage, frequency of injection, or timing
of injection might affect the results. The results in this
study are consistent to other authors’ findings that GFs in
PRP were higher in their other studies. However, the abso-
lute amount of the GFs was different, as Delos et al.
reported PDGF-AB, VEGF, and TGF-β1 concentrations in
whole blood or PRP were 125 vs 330 pg/ml, 10 vs 18 pg/
ml pg/ml, and 32 vs 85 ng/ml respectively (Delos et al.
2014), Hammnod et al. reported that concentrations of
PDGF in plasma or PRP was 4150 vs 20,745 pg/ml
(Hammond et al. 2009), and Bir SC reported that concen-
trations of PDGF and VEGF in plasma or PRP was 30 vs
53 pg/ml and 958 vs 45,352 pg/ml respectively (Bir et al.
2011). The constituents of PRP might be also affected by
the condition of patients or animals before blood is har-
vested. Additional research is needed to define the effects
of these variables and applications on PRP. Finally, skeletal
muscle fibrosis in this study might be affected by the
fibrosis part of the bone healing/callus to some extent.
Conclusions
In conclusion, skeletal muscle fibrosis caused by distraction
osteogenesis persisted even in the GC muscles of the PRP
group. At least in this study, we found no significant differ-
ence in muscle fibrosis between the PRP and non-PRP
groups, and we could not show that PRP had favorable
effects on skeletal muscle fibrosis. To our knowledge, this is
the first report about the effect of PRP on skeletal muscle
fibrosis following distraction osteogenesis. We should not
use PRP for skeletal muscle following distraction osteogen-
esis just because PRP is a modern therapeutic approach.
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